AIM ImmunoTech enrolls, doses first subject in Phase 2 study on Ampligen

AIM ImmunoTech announced it has enrolled and dosed the first subject in the company’s Phase 2 study evaluating Ampligen as a potential therapeutic for people with post-COVID conditions. This important study milestone follows on the heels of the company having recently opened multiple clinical study sites and having screened numerous subjects. AIM Chief Executive Officer Thomas K. Equels commented, “We have clinical sites up and running, and we expect additional sites to be open in the very near future. AIM knows how vital it is to keep building on this momentum. By developing Ampligen as a therapeutic for Long COVID with chronic fatigue-like symptoms, we are working to bring hope to the millions of people struggling with this debilitating and life-altering syndrome. Long COVID is a major unmet medical need – in other words, there is no approved therapy available for this major health problem, and we believe that Ampligen has the potential to be a therapeutic solution.” AMP-518 is expected to enroll approximately 80 subjects between the ages of 18 to 60 years across up to 10 centers in the United States. Subjects will be randomized 1:1 to receive twice weekly IV infusions of Ampligen or placebo for 12 weeks, with a follow-up phase of two weeks.